PMOD TECHNOLOGIES GMBH

Their core work

PMOD Technologies develops and distributes the PMOD software platform — a widely used commercial tool for quantitative analysis of PET, SPECT, and MRI images in biomedical research settings. Their software handles kinetic modeling, image registration, region-of-interest analysis, and tracer quantification, tasks that PET researchers worldwide depend on for reproducible, publication-grade results. In both H2020 projects, PMOD participated as a third-party contributor rather than a full research partner, providing access to their software tools and expertise to support PhD training networks. Their business model is software licensing to academic hospitals, pharmaceutical companies, and research institutes — they do not perform primary research themselves but enable the quantitative imaging work of others.

What they specialise in

How they've shifted over time

With both projects clustered tightly in 2017–2018 and no keyword data attached to HYBRID, the evolution visible in this dataset is limited but telling. The first project (HYBRID) appears to be a broad entrepreneurship-oriented training network with no domain-specific keywords, suggesting PMOD contributed general software access or business-model know-how. By 2018, PET-AlphaSy shows a sharply focused application: PET imaging of alpha-synuclein as a Parkinson's disease biomarker — a technically demanding, clinically relevant use case for their software. The direction is from broad training participation toward specialized neuroimaging and neurodegenerative disease research as the primary application domain.

PMOD's most recent H2020 involvement points toward high-specificity neuroimaging — PET quantification for neurodegenerative disease biomarkers — which aligns with growing pharmaceutical industry demand for validated imaging endpoints in Parkinson's and Alzheimer's trials.

How they like to work

PMOD joined both projects exclusively as a third party, meaning they contributed tools or services under contract to the consortium rather than as a named research partner. This is a recurring pattern for software companies in MSCA networks: they provide platform access, training workshops, or data analysis pipelines to doctoral candidates without bearing primary research responsibilities. Working with PMOD likely means accessing their software through a research license or service agreement, not co-designing experiments — they are a resource, not a co-investigator.

Despite only two projects, PMOD's consortia exposed them to 37 unique partners across 10 countries — an unusually broad network for a two-project portfolio, reflecting the large multi-institution structure typical of MSCA-ITN networks. Their partners are predominantly academic research hospitals and university departments active in nuclear medicine and radiopharmaceutical sciences across Europe.

What sets them apart

PMOD occupies a narrow but defensible niche: they are one of a handful of commercial vendors whose software is accepted as a standard tool in peer-reviewed PET research, giving them credibility in grant applications that generic image analysis packages lack. For a consortium building an MSCA or EIC project that includes PET imaging work, listing PMOD as a third-party partner signals methodological rigor and provides researchers with validated, well-documented analysis workflows. Their Swiss base and SME status also make them an attractive partner for projects requiring non-EU associated country participation.

Highlights from their portfolio

• PET-AlphaSy
  Directly applied PMOD's imaging platform to one of the most active areas in neurodegeneration research — PET quantification of alpha-synuclein aggregates as a Parkinson's disease biomarker — connecting a software SME to high-value pharmaceutical imaging endpoints.
• HYBRID
  An MSCA-ITN entrepreneurship training network that recruited PMOD as a third-party contributor, demonstrating the company's willingness to engage with doctoral training programs beyond pure technical software provision.